RxDoctor Payments DataLook up a doctor →

Charles Wells, MD

Sleep Medicine · Macon, GANPI 1053332841

Payments from drug & device makers

$400,807in general payments, 2019–2025

Across 532 payments — averaging $753.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$284K
  • Jazz Pharmaceuticals Inc.$115K
  • Harmony Biosciences LLC$1K
  • Axsome Therapeutics, Inc.$253
  • ZOLL Respicardia, Inc.$157
  • Resmed Corp$145
  • plus $337 from 8 others

What the payments were for

  • Food & beverage$2,59288%
  • Education$37012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$400,807 in reported general payments places this provider in the 95th percentile of 50 sleep medicine providers in Georgia.

See all sleep medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$418,575
Medicare patients
1,550
Services billed
4,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl20$158,120
BetaseronInterferon Beta-1b13$123,246
BelsomraSuvorexant75$34,410
SunosiSolriamfetol Hcl22$19,178
NeuproRotigotine14$15,995
Modafinil112$9,233
QuviviqDaridorexant Hcl13$6,335
Armodafinil48$3,710
Trazodone Hcl617$3,409
Eszopiclone35$2,510
Gabapentin174$1,929
Doxepin Hcl123$1,756
Ramelteon14$1,660
Ropinirole Hcl26$1,633
Pramipexole DihydrochloridePramipexole Di-Hcl69$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$1,162$158,12020 claims
MerckBelsomra$27$34,41075 claims
Axsome Therapeutics, Inc.Sunosi$253$19,17822 claims
Idorsia Pharmaceuticals US IncQuviviq$37$6,33513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 sleep medicine providers in Georgia.

Other sleep medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →